Setterwalls advisor in revocation of pharma patent

Setterwalls has successfully represented Sandoz in a patent dispute against AstraZeneca.

The dispute concerned AstraZeneca’s patent for a sustained release formulation of the medicinal product quetiapine, which is used for the treatment of schizophrenia and certain depressive disorders. Sandoz, who had launched a competing medicinal product on the market, sued AstraZeneca for revocation of the patent in 2014.

In a judgment made on 31 May 2016, the District Court of Stockholm agreed with Sandoz. The Court revoked the patent and lifted its previous preliminary injunctions against the sale of Sandoz’ products with immediate effect.